Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol. 2001;24:1623 30. S7.2.1-7. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol. 2000;85:981 5. S7.2.1-8. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonisch- emic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964 70. CLINICAL STATEMENTS AND GUIDELINES S7.2.1-9. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of ori- gin of syncope. J Am Coll Cardiol. 1993;21:110 6. S7.2.1-10. Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the out- come of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol. 2008;51:1277 82. S7.2.1-11. Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk car- diomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inap- propriate therapy (MADIT-RIT) study. Circulation. 2014;129:545 52. S7.2.1-12. Piccini JP, Berger JS, O Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245 53. S7.2.1-13. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.2.1-14. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhyth- mia inducibility predicts subsequent ICD activation in nonisch- emic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755 61. S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. 